Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421763 | 0.90 | KIF11 (0.53) | XDHALOX15KDM4EHPGDHSD17B10 | |
| SCHEMBL18814268 | 0.88 | HRH3 (0.72) | HRH3XDHKDM4EHPGDHSD17B10 | |
| SCHEMBL28415588 | 0.88 | EIF4A3 (0.55) | HRH3CASP3SENP8SENP7SENP6 | |
| SCHEMBL21531156 | 0.86 | XDH (0.64) | HRH3XDHKDM4ECHEK2PDGFRB | |
| SCHEMBL6417272 | 0.84 | HRH3 (0.80) | HRH3CASP3SENP8SENP7SENP6 | |
| SCHEMBL6947975 | 0.84 | HRH3 (0.52) | HRH3CASP3SENP8SENP7SENP6 | |
| SCHEMBL30445643 | 0.83 | HSD17B10 (0.61) | HRH3CASP3SENP8SENP7SENP6 | |
| SCHEMBL69851 | 0.83 | HSD17B10 (0.61) | HRH3CASP3SENP8SENP7SENP6 | |
| SCHEMBL8479941 | 0.82 | GABRA1 (0.47) | HRH3XDHALOX15KDM4EALDH1A1 | |
| SCHEMBL6424303 | 0.81 | KIF11 (0.50) | XDHALOX15KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20050178659-A1 | Copolymer compound and electrochemical cell therewith | NEC TOKIN CORPORATION (JP) | 2005-08-18 | — | — | US | disclosed |
| US-5985909-A | Cyclopropylindoles and their seco precursors, and their use as prodrugs | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-11-16 | — | — | US | disclosed |
| EP-0850220-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997007097-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | HRH3 1501/4885CASP3 2480/4885SENP8 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.